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OBJECTIVES: Evaluate, using a markovian probabilistic model, the development of 
renal disease in Fabry Disease(FD), comparing the probability of developing the dif-
ferent stages of renal disease in those with FD using Enzyme replacement therapy 
(ERT) with those not using ERT. METHODS: A model with pre-deﬁ ned 3 possible 
stages was used for patients with FD and renal dysfunction. Progression to a different 
stage or having a stable disease were possible. Less severe ‘stages’ could only migrate 
to more severe ‘stages’. Three year time cycles were used. The probabilities ERT x 
without ERT were compared. RESULTS: Probabilities between the 2 arms: 1)The 
probability of having proteinuria only and being stable in 3 y was 56% in those treated 
versus 48% in those untreated; 2)Also for those with proteinuria only, with ERT the 
probability of progressing to renal impairment in 3 y was reduced, to 24% compared 
to 32% in those untreated; and 3)For those receiving ERT already with renal impair-
ment, but not in dialysis, the probability of postponing the dialysis in 3 y time was 
not modiﬁ ed. CONCLUSIONS: This model did show a relevant improvement with 
ERT for those that were treated at initial stages of renal disease (the subgroup with 
proteinuria only). For this group the probability of remaining in a less severe stage of 
the disease in a 3 y time, postponing renal impairment was signiﬁ cant for those using 
ERT. This was only a preliminar model, considering that the maintenance of less 
severe states of renal disease postpone the need for dialysis in this sub-group, aspects 
such as quality of life will be added in order to do a more complete evaluation. This 
model was build considering clinical outcomes, something new on rare diseases. The 
discussion on how to evaluate and on the value of ‘classical modeling’ in rare diseases 
are still an on going issue with a lot to be elucidated.
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BACKGROUND: Digital ulcers (DU) are difﬁ cult to heal, and can lead to severe, 
disabling complications. The DUO Registry is an international, multi-centre, observa-
tional study to assess outcomes in patients with DU disease associated with Sclero-
derma. OBJECTIVES: To assess the impact of DU on patients’ work, daily activities, 
and dependency. METHODS: A work and daily activities assessment questionnaire 
was completed by the patients at enrollment visit into the DUO registry from April 
2008 to April 2010. An overall score measuring the impairment in daily activities and 
in work was calculated. In addition, the number of hours of help needed was deter-
mined. Overall mean (SD) as well as stratiﬁ ed analyses by number of DU were per-
formed. RESULTS: At the cut-off date for this analysis, 1770 questionnaires were 
received from patients enrolled in the registry. The questionnaire was completed by 
71% (n = 1250), of which 35% patients were employed. The majority of patients 
completing the questionnaire were female (82%) with a mean age of 54 years. Prob-
lems associated with DU reduced the ability of patients to perform regular daily 
activities by 52% (SD 30). More than 50% of the patients needed help due to their 
DU during the previous month, with an average of 7 hours (SD 29) of paid help and 
36 hours (SD 101) of unpaid help. The productivity of patients working was reduced 
by 40% (SD 31). Patients with one or more DU present at enrolment and completing 
the questionnaire (72% of all completers) were more impaired in their daily activities 
(38%, 52%, 55%, 63% for patients with 0, 1, 2, ≥3 DUs, respectively) and work 
(32%, 40%, 41%, 47% for patients with 0, 1, 2, ≥3 DU, respectively). CONCLU-
SIONS: DU impose a signiﬁ cant burden on patients’ by impacting their daily life and 
ability to work as shown in patients enrolled in the DUO Registry.
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OBJECTIVES: To better understand current practice patterns and determine how 
current practice ﬁ ts recently published guidelines, a treatment sequencing analysis of 
ITP patients in Spain was conducted. METHODS: A retrospective chart review of 
patients diagnosed with ITP was undertaken at 8 hospitals in Spain, collecting demo-
graphic and clinical data, drug treatment (up to ﬁ fth line) and its duration. Throm-
bopoetin-receptor agonists were not available at the time of the review. RESULTS: 
Data on 60 patients [90% (n = 54) with baseline platelet counts <30 × 109/L and 10% 
(n = 6) <50 × 109/L with bleeding episodes] were available. Patients were 54.4 ± 20.7 
(SD) years of age, 63% female, and 6.0 ± 7.2 (SD) years since diagnosis. The most 
common ﬁ rst-line treatment was corticosteroids (n = 39, 65%), followed by intrave-
nous immunoglobulins (IVIg; n = 19, 32%). The mean duration of ﬁ rst-line treatment 
with corticosteroids was 28.2 ± 39.0 (SD) days. The most common sequence of treat-
ment for patients initially treated with corticosteroids was administration of four 
additional courses with corticosteroids (18/39, 46%), followed by alternation between 
IVIg and corticosteroids until the ﬁ fth-line of treatment (7/39, 18%). Of the 19 
patients with initial IVIg, 5 (26%) received corticosteroids in the 4 remaining treat-
ments, 5 (26%) continued with IVIg, and 4 (21%) alternated corticosteroids and IVIg. 
In total, 41 patients (68%) received ≥2 treatments with corticosteroids and 10 (17%) 
received treatments other than corticosteroids and IVIg (3 patients received azathio-
prine, 3 rituximab, 2 platelet transfusions, 1 anti-D immunoglobulin, 1 danazol and 
1 mycophenolate mofetil). CONCLUSIONS: Patterns of treatment of ITP in Spain 
usually followed recently introduced recommendations from international consensus 
guidelines. However, in most patients, corticosteroid treatment was given repeatedly, 
which exceeds current recommendations, i.e., rapidly tapering corticosteroid dose and 
stopping after 4 weeks. Future research is needed with a larger sample size, to explore 
the place of splenectomy in treatment sequencing, and better understand the role of 
combination therapy. 
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OBJECTIVES: Web-based administration of health utility interviews offers the poten-
tial to recruit larger, more representative samples with reduced time and costs com-
pared to FTF administration. This analysis compared health utilities elicited through 
web vs. FTF administration. METHODS: Six distinct ITP health states were included 
in a TTO and visual analogue scale (VAS)-based health utility valuation, which was 
administered FTF (n = 63) and via web (n = 359) to members of the UK general public. 
The Wilcoxon rank-sum test was used to compare utilities between methods. The 
interaction between administration method and respondent characteristics was 
assessed by regression analyses on each pair of health utilities. An additional analysis 
of exclusion criteria was conducted from least strict to most strict. RESULTS: Demo-
graphic characteristics in the FTF and web survey were generally comparable to the UK 
general population 2001 census data. The mean time to complete the TTO survey was 
10.2 minutes in the FTF and 9.9 minutes in the web survey. Valid TTO response rates 
were higher in the FTF sample (85% to 96%) compared to the web sample (58% to 80%) 
across health states. Higher proportions of web respondents reported that the TTO 
exercise was ‘very’ or ‘somewhat unclear’ (17 % vs. none) or that all or most decisions 
were difﬁ cult to make (41% vs. 30%) compared to the FTF sample. Utilities were statisti-
cally signiﬁ cantly lower in the web vs. the FTF survey (P < 0.05). TTO scores were sensitive 
to the selection of exclusion criteria. The variation in TTO scores was smaller among FTF 
vs. web respondents. VAS ratings were similar across the two administration methods and 
less sensitive to exclusion criteria selection. CONCLUSIONS: Our study highlighted 
trade-offs between the advantages and challenges of web administration. More 
research is warranted to further improve data quality in web-based utility surveys.
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OBJECTIVES: To predict EQ-5D utilities from neuropathic pain scores using indirect 
mapping of pain scores to EQ-5D item responses subsequently converted into utilities 
or direct mapping of pain scores into utilities. METHODS: Mappings were based on 
baseline data from three longitudinal surveys of adults (n = 2,719) who had ≥3 months 
of painful diabetic peripheral neuropathy (pDPN) or post-herpetic neuralgia (PHN), 
were receiving pain medications, and completed EQ-5D and pain questionnaires. In 
indirect mapping, ordered logit regression was used to predict and simulate EQ-5D 
responses using the following predictors: age, gender, and pain scores ranging from 0 
(“no pain”) to 10 (“pain as bad as you can imagine”). Utilities were computed based 
on predicted responses using a U.S. algorithm. In direct mapping, OLS regression was 
used to directly predict utilities using the same predictors. Cross-validations were 
conducted separately in pDPN and PHN respondents. Comparisons were made 
between actual and estimated values on mean utilities, mean square/absolute errors 
(MSE/MAE). RESULTS: Both estimated utilities were consistent with actual values 
along the increment/decrement of the pain scores. Direct mapping explained 29% of 
the variance and had an estimated mean utility close to the observed data [0.594 (MSE 
= 0.31; MAE = 0.148)]. Indirect mapping resulted in lower mean utility [0.588 (MSE 
= 0.054; MAE = 0.184)] but its distribution was more consistent with the actual values. 
